Free Trial

Lakeshore Biopharma Q3 2024 Earnings Report

Lakeshore Biopharma logo
$2.51 +0.01 (+0.40%)
As of 03/28/2025 03:47 PM Eastern

Lakeshore Biopharma EPS Results

Actual EPS
-$1.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lakeshore Biopharma Revenue Results

Actual Revenue
$23.82 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lakeshore Biopharma Announcement Details

Quarter
Q3 2024
Time
N/A

Conference Call Resources

Remove Ads

Lakeshore Biopharma Earnings Headlines

LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval
Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
See More Lakeshore Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lakeshore Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakeshore Biopharma and other key companies, straight to your email.

About Lakeshore Biopharma

Lakeshore Biopharma (NASDAQ:LSB) Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

View Lakeshore Biopharma Profile

More Earnings Resources from MarketBeat